Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Desai PM, et al. Among authors: kambhampati s. J Clin Oncol. 2021 Oct 10;39(29):3261-3272. doi: 10.1200/JCO.20.01739. Epub 2021 Jun 22. J Clin Oncol. 2021. PMID: 34156898 Free PMC article. Clinical Trial.
A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.
Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD. Reed GA, et al. Among authors: kambhampati s. Cancer Med. 2016 Nov;5(11):3031-3040. doi: 10.1002/cam4.845. Epub 2016 Oct 13. Cancer Med. 2016. PMID: 27734609 Free PMC article. Clinical Trial.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Platzbecker U, et al. Among authors: kambhampati s. Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1. Lancet Haematol. 2015. PMID: 26686043 Clinical Trial.
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR; ONTIME study investigators. Garcia-Manero G, et al. Among authors: kambhampati s. Lancet Oncol. 2016 Apr;17(4):496-508. doi: 10.1016/S1470-2045(16)00009-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968357 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36163845
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Parmar S, Smith J, Sassano A, Uddin S, Katsoulidis E, Majchrzak B, Kambhampati S, Eklund EA, Tallman MS, Fish EN, Platanias LC. Parmar S, et al. Among authors: kambhampati s. Blood. 2005 Oct 1;106(7):2436-43. doi: 10.1182/blood-2004-10-4003. Epub 2005 Mar 24. Blood. 2005. PMID: 15790787 Free PMC article.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, Barrientos JC, Rai KR, Reeves JA, Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik AP, Roeker L, Fonseca GA, Sitlinger A, Hamadeh IS, Dorsey C, LaRatta N, Weissbrot H, Luning Prak ET, Tsao P, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Svoboda J, Brander DM. Mato AR, et al. Among authors: kambhampati s. Blood. 2021 May 20;137(20):2817-2826. doi: 10.1182/blood.2020007376. Blood. 2021. PMID: 33259589 Free PMC article. Clinical Trial.
Activation of protein kinase C delta by all-trans-retinoic acid.
Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmar S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LC. Kambhampati S, et al. J Biol Chem. 2003 Aug 29;278(35):32544-51. doi: 10.1074/jbc.M301523200. Epub 2003 Jun 12. J Biol Chem. 2003. PMID: 12805378 Free article.
282 results